Anavex up on plans to seek regulatory approval for lead drug in Europe

Anavex Life Sciences

19/12/2023 18:13

** Shares of drug developer Anavex Life Sciences Corp
 AVXL.O  rise 13.7% to $10
    ** AVXL plans to submit application to market its lead drug
candidate as a potential Alzheimer's disease treatment in Europe
next year
    ** Co says European Medicines Agency's health regulatory
body agreed that it is eligible to submit marketing application
for the experimental drug under a centralised procedure 
    ** The drug blarcamesine or ANAVEX 2-73, if approved, would
allow to be marketed in all European Union member states 
    ** Co said mid- to-late-stage trial data showed that in
addition to significant improvement in dementia symptoms, the
drug also showed reduction of brain volume loss and pathological
aggregation of amyloid
    ** The trial data will be published in an upcoming
peer-reviewed journal - AVXL
    ** Including session's gain, stock up 7.8% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))